Levick

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Faculty, GSK, Royal college, University, Drug development, Senior, Tropical medicine, G protein-coupled receptor, Levick, University of Cambridge, Membership of the Royal College of Physicians of Ireland, Cancer, ETH Zurich, Faculty of Pharmaceutical Medicine, Multimedia, Biomarker, Computational chemistry, Doctor of Philosophy, Language, Paul Scherrer Institute, GPCR, Novartis, MD, Vivo, Drug discovery, Commonwealth Scholarship and Fellowship Plan, Artificial intelligence, Marie Cassidy, FRCPA, University of Newcastle, Pharmaceutical medicine, Pharmacology, Medical device, Pharmaceutical industry, EU, Physician, AI

InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.

Key Points: 
  • InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
    Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
    Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ.
  • In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
  • Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

Conversations with American Legends: Ambassador Andrew Young Discusses the U.S.’ Standing on the World Stage

Retrieved on: 
Friday, August 14, 2020
Activists, Baptists, Activism, Selma to Montgomery marches, Civil rights movement, Liberalism in the United States, Martin Luther King Jr., Montgomery bus boycott, Levick, Memphis, Tennessee

Andrew Youngaddress some of the most pressing concerns of the day from racial unrest and worsening economic disparities, to the impact of COVID and the faltering reputation of America on the world stage.

Key Points: 
  • Andrew Youngaddress some of the most pressing concerns of the day from racial unrest and worsening economic disparities, to the impact of COVID and the faltering reputation of America on the world stage.
  • Young, now 88, was a close colleague of Martin Luther King, Jr., and was there in Memphis on the day King was assassinated.
  • Jimmy Carter named him as an Ambassador to the U.N., the first African-American to serve in that role.
  • Young will be interviewed by Richard Levick, Esq., Chairman & CEO, LEVICK and Bill Ide, III, Partner, Corporate Governance, Akerman.